Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells
Anders W. Matson, Robert Hullsiek, Kate J. Dixon, Sam C. Wang, Anders J. Lindstedt, Ryan R. Friess, Shee Kwan Phung, Tanya S. Freedman, Martin Felices, Emily Nestor Truckenbrod, Jianming Wu, Jeffrey S. Miller, Bruce K. Walcheck
This study shows that an ADAM17-blocking antibody enhances IL-15-mediated NK cell activation and proliferation through CD16A and CD137, with potential therapeutic applications in cancer.
Journal for ImmunoTherapy of Cancer · Jul 1, 2024Peer-reviewedImmunology